RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Zealand Pharma A/S - Stock

Zealand Pharma A/S Net Income 2024

Zealand Pharma A/S Net Income

-968.31 M DKK

Ticker

ZEAL.CO

ISIN

DK0060257814

WKN

A0YJW7

In 2024, Zealand Pharma A/S's profit amounted to -968.31 M DKK, a 37.59% increase from the -703.74 M DKK profit recorded in the previous year.

The Zealand Pharma A/S Net Income history

YEARNET INCOME (undefined DKK)
2029e2.4
2028e-1.08
2027e-0.84
2026e0.43
2025e-0.57
2024e-0.97
2023-0.7
2022-1.2
2021-1.02
2020-0.85
2019-0.57
20180.58
2017-0.27
2016-0.16
2015-0.11
2014-0.06
2013-0.18
20120.04
20110.01
2010-0.1
2009-0.08
2008-0.03

Zealand Pharma A/S Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Zealand Pharma A/S, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Zealand Pharma A/S from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Zealand Pharma A/S’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Zealand Pharma A/S. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Zealand Pharma A/S’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Zealand Pharma A/S’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Zealand Pharma A/S’s growth potential.

Zealand Pharma A/S Revenue, EBIT and net profit per share

DateZealand Pharma A/S RevenueZealand Pharma A/S EBITZealand Pharma A/S Net Income
2029e3.98 B undefined0 undefined2.4 B undefined
2028e1.91 B undefined402.56 M undefined-1.08 B undefined
2027e1.06 B undefined-335.57 M undefined-835.79 M undefined
2026e1.18 B undefined1.7 B undefined429.41 M undefined
2025e819.92 M undefined-481.29 M undefined-571.15 M undefined
2024e195.73 M undefined-523.07 M undefined-968.31 M undefined
2023342.79 M undefined-561.24 M undefined-703.74 M undefined
2022103.99 M undefined-775.86 M undefined-1.2 B undefined
2021108.55 M undefined-782.14 M undefined-1.02 B undefined
2020192 M undefined-602.3 M undefined-846.73 M undefined
201941.33 M undefined-573.18 M undefined-571.54 M undefined
201837.98 M undefined-463.5 M undefined581.28 M undefined
2017136.32 M undefined-248.53 M undefined-274.41 M undefined
2016230.86 M undefined-96.31 M undefined-157.3 M undefined
2015187.68 M undefined-64.38 M undefined-113.96 M undefined
2014153.77 M undefined-73.54 M undefined-64.99 M undefined
20136.6 M undefined-185.6 M undefined-183.7 M undefined
2012223.6 M undefined32.4 M undefined36.4 M undefined
2011142.3 M undefined8.8 M undefined13.4 M undefined
201087.4 M undefined-108.7 M undefined-104.6 M undefined
200925.3 M undefined-80.6 M undefined-76.4 M undefined
200856.3 M undefined-44.7 M undefined-33.7 M undefined

Zealand Pharma A/S stock margins

The Zealand Pharma A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zealand Pharma A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zealand Pharma A/S.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Zealand Pharma A/S's sales revenue. A higher gross margin percentage indicates that the Zealand Pharma A/S retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Zealand Pharma A/S's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Zealand Pharma A/S's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Zealand Pharma A/S's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Zealand Pharma A/S. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Zealand Pharma A/S's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Zealand Pharma A/S Margin History

Zealand Pharma A/S Gross marginZealand Pharma A/S Profit marginZealand Pharma A/S EBIT marginZealand Pharma A/S Profit margin
2029e94.41 %0 %60.21 %
2028e94.41 %21.04 %-56.44 %
2027e94.41 %-31.78 %-79.15 %
2026e94.41 %143.75 %36.27 %
2025e94.41 %-58.7 %-69.66 %
2024e94.41 %-267.24 %-494.72 %
202394.41 %-163.73 %-205.3 %
2022100 %-746.12 %-1,156.05 %
202189.89 %-720.56 %-937.99 %
2020100 %-313.7 %-441 %
201999 %-1,386.73 %-1,382.77 %
201894.41 %-1,220.47 %1,530.61 %
201794.41 %-182.31 %-201.3 %
201694.41 %-41.72 %-68.13 %
201594.41 %-34.3 %-60.72 %
201491.04 %-47.82 %-42.26 %
201394.41 %-2,812.12 %-2,783.33 %
201294.41 %14.49 %16.28 %
201194.41 %6.18 %9.42 %
201094.41 %-124.37 %-119.68 %
200994.41 %-318.58 %-301.98 %
200894.41 %-79.4 %-59.86 %

Zealand Pharma A/S Aktienanalyse

What does Zealand Pharma A/S do?

Zealand Pharma A/S is a biopharmaceutical company specializing in the discovery and development of therapeutics, particularly in the field of diabetes, gastrointestinal, and metabolic diseases. The company aims to improve the quality of life for patients with chronic conditions. Zealand Pharma's business model is based on the discovery, development, and commercialization of novel peptide-based therapeutics, utilizing their own technology platform and partnering with pharmaceutical industry collaborators. Their portfolio includes innovative product candidates such as the diabetes treatment Adlyxin and Lixisenatide, both GLP-1 agonists developed in collaboration with Sanofi. They also have products for the treatment of gastrointestinal and heart diseases. Zealand Pharma has a wide pipeline of product candidates at various stages of development, including for the treatment of obesity, fatty liver diseases, and other metabolic conditions. The company works closely with partners such as Sanofi, Boehringer Ingelheim, and Roche. Zealand Pharma is listed on NASDAQ OMX Copenhagen and employs over 200 people in Denmark and the USA. Overall, Zealand Pharma is an innovative biopharmaceutical company with a diverse portfolio of product candidates, focused on collaboration to accelerate product development and improve the quality of life for patients with chronic conditions. Zealand Pharma A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Zealand Pharma A/S's Profit Margins

The profit margins of Zealand Pharma A/S represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Zealand Pharma A/S's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Zealand Pharma A/S's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Zealand Pharma A/S's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Zealand Pharma A/S’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Zealand Pharma A/S stock

How much profit has Zealand Pharma A/S made this year?

Zealand Pharma A/S has made -968.31 M DKK this year.

How has the profit developed compared to last year?

The profit has increased by 37.59% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Zealand Pharma A/S publish its earnings?

Zealand Pharma A/S publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Zealand Pharma A/S?

The profits of Zealand Pharma A/S are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Zealand Pharma A/S?

You can learn more about the earnings of Zealand Pharma A/S by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Zealand Pharma A/S pay?

Over the past 12 months, Zealand Pharma A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zealand Pharma A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of Zealand Pharma A/S?

The current dividend yield of Zealand Pharma A/S is .

When does Zealand Pharma A/S pay dividends?

Zealand Pharma A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zealand Pharma A/S?

Zealand Pharma A/S paid dividends every year for the past 0 years.

What is the dividend of Zealand Pharma A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zealand Pharma A/S located?

Zealand Pharma A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zealand Pharma A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zealand Pharma A/S from 7/6/2024 amounting to 0 DKK, you needed to have the stock in your portfolio before the ex-date on 7/6/2024.

When did Zealand Pharma A/S pay the last dividend?

The last dividend was paid out on 7/6/2024.

What was the dividend of Zealand Pharma A/S in the year 2023?

In the year 2023, Zealand Pharma A/S distributed 0 DKK as dividends.

In which currency does Zealand Pharma A/S pay out the dividend?

The dividends of Zealand Pharma A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Zealand Pharma A/S

Our stock analysis for Zealand Pharma A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zealand Pharma A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.